Model can predict the evolution of new covid variants
Evolutionary information can support the design of targeted vaccines
During the SARS-CoV-2 pandemic, a new majority variant replaced the previous one in successive epidemic waves. By now, the evolution of the virus has become more complicated: Several variants are globally circulating at the same time and compete with each other. This is where predictive models become important to identify those variants that will likely rise to predominance in the near future.
On the one hand, new variants have intrinsic changes that can increase transmissibility. On the other hand, previous infections or vaccinations have generated immunity to older variants. The new model uses these factors to calculate fitness differences between variants. The analysis is based on massive, internationally collected experimental data, sequence data, and case numbers of infections and vaccinations.
The study shows that human immunity has now become the main driving force of the evolution of SARS-CoV-2. “This means that even after the pandemic is over, the virus will continue to produce new variants, and we need timely data on them. Our results show how important continued, internationally coordinated surveillance of the SARS-CoV-2 virus is,” said Professor Dr Michael Lässig from the Cologne Institute for Biological Physics and leader of the study. “Predictions of viral evolution obtained from these data can help to design vaccines that are optimally effective against future variants.” Lässig’s lab has been working on predictive analysis of the flu virus for years and advises the World Health Organization on the selection of influenza vaccines.
The study was carried out at the Center for Predictive Analysis of Viral Evolution (Previr), an international, interdisciplinary research center based at the University of Cologne. Research at Previr focuses on a better understanding of viral evolution for public health.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.